公开(公告)号：EP3261663A1

公开(公告)日：2018-01-03

申请号：EP16756100.0

申请日：2016-02-22

申请人： Merck Sharp & Dohme Corp.

发明人： REICHERT, Paul ,  PROSISE, Winifred, W. ,  SCAPIN, Giovanna ,  YANG, Xiaoyu ,  KASHI, Ramesh ,  STRICKLAND, Corey

IPC分类号： A61K39/00

CPC分类号： C07K16/2818 ,  C07K16/00 ,  C07K2317/24 ,  C07K2317/76

摘要： Crystals of pembrolizumab and structurally similar anti-PD-1 monoclonal antibodies are provided, as well as methods of producing such crystals, and uses of compositions comprising such antibody crystals, e.g. in treatment of cancers. The present invention satisfies these needs and more by providing pembrolizumab crystals and a method producing pembrolizumab crystals. One embodiment of the method of the invention produces crystals suitable for X-ray diffraction, and the inventors herein used such crystals to solve the three-dimensional structure of pembrolizumab to 2.3 A resolution.

公开(公告)号：EP3873941A1

公开(公告)日：2021-09-08

申请号：EP19878489.4

申请日：2019-10-28

申请人： Merck Sharp & Dohme Corp.

发明人： REICHERT, Paul ,  PROSISE, Winifred, W. ,  YANG, Xiaoyu ,  STRICKLAND, Corey ,  NARASIMHAN, Chakravarthy Nachu ,  FISCHMANN, Thierry, O. ,  WALSH, Erika, R. ,  SU, Yongchao

IPC分类号： C07K16/28

公开(公告)号：EP2866833B1

公开(公告)日：2019-05-15

申请号：EP13808570.9

申请日：2013-06-25

申请人： Merck Sharp & Dohme Corp.

发明人： REICHERT, Paul ,  PROSISE, Winifred, W. ,  ORTH, Peter ,  NARASIMHAN, Chakravarthy ,  KASHI, Ramesh, S.

IPC分类号： A61K39/395 ,  C07K16/24

公开(公告)号：EP2866833A2

公开(公告)日：2015-05-06

申请号：EP13808570.9

申请日：2013-06-25

申请人： Merck Sharp & Dohme Corp.

发明人： REICHERT, Paul ,  PROSISE, Winifred, W. ,  ORTH, Peter ,  NARASIMHAN, Chakravarthy ,  KASHI, Ramesh, S.

IPC分类号： A61K39/395

CPC分类号： C07K16/244 ,  A61K39/39591 ,  C07K2299/00 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e. they maintain biological activity of the anti-huiL-23 antibody, such as anti-huiL-23p 19 antibody, longer than corresponding solution formulations.